Showing results (91-100 of 159) with videos related to
Sort By:
Pageof 16
Dermatology (Basel, Switzerland)|October 13, 2006
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasisCraig L Leonardi, Darryl Toth, Jennifer C Cather, et al.Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis RegistryWayne P Gulliver, Kyoungah See, Baojin Zhu, et al.Advances in Therapy|November 22, 2019
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated AnalysisGerd R Burmester, Kenneth B Gordon, James T Rosenbaum, et al.Archives of Dermatology|June 22, 2005
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysisAdam M Quinn, Kimberly Brown, Brian K Bonish, et al.Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.The Journal of Investigative Dermatology. Symposium Proceedings|October 31, 2006
Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammationBrian J Nickoloff, Brian K Bonish, Deborah J Marble, et al.American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|December 11, 2002
Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgerySharon Gohari, Charles Gambla, Mary Healey, et al.JAMA|December 18, 2003
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, et al.Journal of the American Academy of Dermatology|March 9, 2025
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 studyKenneth B Gordon, Matthias Augustin, Jonathan Barker, et al.Pageof 16